Metraipolis › archive › dc_4745bb432bdd
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions — Europe PMC PMID:42153199
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42153199
- DOI
- 10.1177/20552173261449688
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T13:17:29.881Z
- SHA-256 of the archived text
656fb70d2d0b935452f8188a70ed2d33c43b2ad5a2984ba5efd7291c4abf1151- Stable URL of this page
https://metraipolis.com/documento/dc_4745bb432bdd
How to cite
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions — Europe PMC PMID:42153199 — Europe PMC (en), https://europepmc.org/article/MED/42153199 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4745bb432bdd (Metraipolis archive dc_4745bb432bdd, sha256 656fb70d2d0b935452f8188a70ed2d33c43b2ad5a2984ba5efd7291c4abf1151)
BibTeX
@misc{dc4745bb432bdd,
title = {Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions — Europe PMC PMID:42153199},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42153199},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4745bb432bdd; sha256 656fb70d2d0b935452f8188a70ed2d33c43b2ad5a2984ba5efd7291c4abf1151},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42153199. Agents can read the archived copy with the MCP tool read_document.